Consolidating the value of fondaparinux for current treatment of non-ST-elevation acute coronary syndromes

Angelo Silverio; Gennaro Galasso; Giuseppe De Luca

doi:10.1016/j.ijcard.2021.04.002

Consolidating the value of fondaparinux for current treatment of non-ST-elevation acute coronary syndromes

Int J Cardiol. 2021 Jul 15:335:21-23. doi: 10.1016/j.ijcard.2021.04.002. Epub 2021 Apr 9.

Authors

Angelo Silverio¹, Gennaro Galasso¹, Giuseppe De Luca²

Affiliations

¹ Department of Medicine, Surgery and Dentistry, University of Salerno, Baronissi, Salerno, Italy.
² Division of Cardiology, Azienda Ospedaliera-Universitaria "Maggiore della Carità", Eastern Piedmont University, Novara, Italy. Electronic address: giuseppe.deluca@maggioreosp.novara.it.

PMID: 33839173
DOI: 10.1016/j.ijcard.2021.04.002

No abstract available

Keywords: Anticoagulation; Coronary artery disease; Fondaparinux; Myocardial infarction; Non-ST-elevation acute coronary syndrome; Percutaneous coronary intervention.

Publication types

Editorial
Comment

MeSH terms

Acute Coronary Syndrome* / drug therapy
Anticoagulants
Fondaparinux
Heparin
Humans

Substances

Anticoagulants
Heparin
Fondaparinux